Next Article in Journal
Silver Nanoparticle Targets Fabricated Using Chemical Vapor Deposition Method for Differentiation of Bacteria Based on Lipidomic Profiles in Laser Desorption/Ionization Mass Spectrometry
Next Article in Special Issue
Characterization of blaKPC-2 and blaNDM-1 Plasmids of a K. pneumoniae ST11 Outbreak Clone
Previous Article in Journal
ESKAPEE Pathogen Biofilm Control on Surfaces with Probiotic Lactobacillaceae and Bacillus species
Previous Article in Special Issue
Occurrence of cfr-Positive Linezolid-Susceptible Staphylococcus aureus and Non-aureus Staphylococcal Isolates from Pig Farms
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 5
10.3390/antibiotics12050872
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae

by
Maria V. Golikova
1,*,
Elena N. Strukova
1,
Kamilla N. Alieva
1,
Vladimir A. Ageevets
2,
Alisa A. Avdeeva
2,
Ofeliia S. Sulian
2 and
Stephen H. Zinner
3
1
Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, 119021 Moscow, Russia
2
Pediatric Research and Clinical Center for Infectious Diseases, 9 Prof. Popov Street, 197022 St. Petersburg, Russia
3
Department of Medicine, Harvard Medical School, Mount Auburn Hospital, 330 Mount Auburn St., Cambridge, MA 02138, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(5), 872; https://doi.org/10.3390/antibiotics12050872
Submission received: 14 April 2023 / Revised: 5 May 2023 / Accepted: 7 May 2023 / Published: 8 May 2023
(This article belongs to the Special Issue Antimicrobial Resistance Mechanisms: Occurrence, Dissemination, Detection and Treatment)
Browse Figures
Review Reports Versions Notes

Abstract

:
The minimal inhibitory concentration (MIC) is conventionally used to define in vitro levels of susceptibility or resistance of a specific bacterial strain to an antibiotic and to predict its clinical efficacy. Along with MIC, other measures of bacteria resistance exist: the MIC determined at high bacterial inocula (MICHI) that allow the estimation of the occurrence of inoculum effect (IE) and the mutant prevention concentration, MPC. Together, MIC, MICHI and MPC represent the bacterial “resistance profile”. In this paper, we provide a comprehensive analysis of such profiles of K. pneumoniae strains that differ by meropenem susceptibility, ability to produce carbapenemases and specific carbapenemase types. In addition, we have analyzed inter-relations between the MIC, MICHI and MPC for each tested K. pneumoniae strain. Low IE probability was detected with carbapenemase-non-producing K. pneumoniae, and high IE probability was detected with those that were carbapenemase-producing. MICs did not correlate with the MPCs; significant correlation was observed between the MICHIs and the MPCs, indicating that these bacteria/antibiotic characteristics display similar resistance properties of a given bacterial strain. To determine the possible resistance-related risk due to a given K. pneumoniae strain, we propose determining the MICHI. This can more or less predict the MPC value of the particular strain.

1. Introduction

The minimal inhibitory concentration (MIC) is conventionally used to define in vitro levels of the susceptibility or resistance of a specific bacterial strain to an antibiotic and to predict its clinical efficacy [1]. However, even if a microorganism is initially susceptible to the antibiotic, the emergence of resistance during antibacterial therapy can lead to treatment failure. Resistance development during antibiotic exposure can be explained by the mutant selection window (MSW) hypothesis [2,3]. Accordingly, the selection of resistant cells occurs if antibiotic concentration falls into the MSW—the concentration range between the MIC (the lower MSW border) and the mutant prevention concentration, MPC (the upper MSW border). The applicability of the MSW hypothesis has been confirmed for several classes of antibiotics, including fluoroquinolones [4,5], glycopeptides [6,7], oxazolidinones [8,9], cephalosporins [10] and carbapenems [11,12], among others. The upper border of the MSW, the MPC, can predict the emergence of resistance of a given bacterial isolate during antibiotic exposure. Along with the MPC, the risk of antibiotic failure can be predicted by MICs determined at high microbial burdens of 107 CFU/mL (HI, MICHI), i.e., significantly higher than the 105 CFU/mL (SI) used in standard in vitro susceptibility testing (MIC). This is recognized as the inoculum effect (IE) [13] that has been observed with several classes of antibiotics [14,15], especially with beta-lactams and beta-lactam/beta-lactamase inhibitor combinations, whose activity may be significantly decreased at high inocula [16,17]. With Gram-negative bacteria, the main drive of the IE with beta-lactams is the production of bacterial beta-lactamases that confer resistance at high bacterial concentrations. This has been well described in numerous in vitro studies with beta-lactamase-producing Escherichia coli, K. pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii exposed to beta-lactams, including penicillins and aminopenicillins, cephalosporins, carbapenems and monobactams [16,17,18]. Published in vivo data using infected animals have shown decreased effectiveness of cefazolin, cefotaxime, piperacillin-tazobactam, amoxicillin-clavulanate and aztreonam due to the IE [19,20,21,22,23,24]. The clinical relevance of the IE has been confirmed in several studies of patients with staphylococcal bacteremia undergoing cefazolin therapy [25,26]. Understanding the role of the IE with beta-lactams is important in the treatment of high bacterial-burden infections, since decreased antibacterial activity may result in unexpected treatment failures.
In summary, MIC, MICHI and MPC represent the bacterial “resistance profile” that captures in vitro parameters of bacterial resistance responsible for treatment failures. The specific mechanism of resistance might be less important than the inoculum effect or MPC value with some antibiotics. To verify this assumption, we used K. pneumoniae strains that either produce or do not produce carbapenemases. It is important to determine pharmacodynamic characteristics for individual K. pneumoniae strains and to identify possible inter-relations among these susceptibility/resistance measures. Moreover, the ability to produce carbapenemases may influence MPC and MICHI values per se, and may predict resistance risks during meropenem therapy.
Meropenem is a commonly used beta-lactam in clinical practice to treat infections caused by Gram-negative bacteria, including those that produce beta-lactamases. K. pneumoniae produce a wide range of beta-lactamases, including the widespread OXA-48 [27], NDM (New Delhi Metallo-beta-Lactamase) [28,29] and KPC (Klebsiella pneumoniae carbapenemase) [30] carbapenemases. The prevalence of carbapenem-resistant K. pneumoniae clinical isolates in hospitals was repeatedly reported [31,32].
To determine the meropenem “resistance profiles” of K. pneumoniae, to explore the influence of carbapenemase type on MPC and MICHI values, and to find inter-relations among MIC, MICHI and MPC, K. pneumoniae clinical isolates and ATCC strains producing carbapenemases of different types (OXA-48, NDM and KPC), along with carbapenemase-negative strains (control group), were used in the study. In addition, we aimed to explore if the IE occurs with meropenem and how it depends on the bacterial production of different types of carbapenemases.

2. Results

2.1. Susceptibility Testing with Meropenem and K. pneumoniae at SI and HI

The results of susceptibility testing with meropenem and K. pneumoniae isolates at standard and high inocula were divided into four groups, depending on their ability to produce carbapenemases, and their specific types are presented in Table 1. Among each strain group (carbapenemase-negative, OXA-48, KPC and NDM carbapenemase producers), meropenem MICs varied widely from low (≤8 mg/L) to medium or high (up to 512 mg/L). At high inocula, most of the tested strains exhibited higher MIC values than at standard inocula; however, this MIC increase differed according to the production of specific carbapenemases. The most obvious inoculum-related meropenem MIC shift (from 8- to 256-fold) was exhibited by NDM-producing isolates and it was always associated with the IE. Compared to NDM producers, KPC-producing K. pneumoniae were characterized by a less pronounced MIC increase at high bacterial inocula (4- to 16-fold), and the IE was detected in four of the nine strains with MICs ranging from 8 to 32 mg/L; the most resistant strains with MICs of 64 and 128 mg/L did not exhibit an IE.
Among OXA-48-producing K. pneumoniae (8- to 64-fold MIC increases), IE occurred only in meropenem-susceptible isolates with MICs up to 8 mg/L; minimal 2-fold inoculum-induced decrease in meropenem activity occurred with the most resistant K. pneumoniae isolate (MIC of 32 mg/L). Non-carbapenemase-producing K. pneumoniae were not usually prone to the IE, except the two most meropenem-susceptible isolates with MICs of 0.03 and 0.06 mg/L; these strains showed 64- and 32-fold inoculum-related MIC decreases, respectively.
To explore if MICs at high and standard inocula are inter-dependent, the respective data, MIC versus MICHI, for four K. pneumoniae isolate groups were plotted on a single graph (Figure 1).
The poor sigmoid relationship between the MIC and MICHI was observed only with carbapenemase-non-producing K. pneumoniae with r2 = 0.65. However, the low correlation coefficient indicates that non-carbapenemase-producing isolates did not show significant correlations between meropenem MICs at either inoculum densities. Carbapenemase-producing isolates did not show any correlations between meropenem MICs at the two inoculum densities. Therefore, it can be hypothesized that bacterial susceptibilities at different inocula are most likely not inter-related for carbapenemase-producing K. pneumoniae or that this relation is poor for carbapenemase-negative strains. However, data points were stratified depending on the K. pneumoniae group: lower MICHIs were detected with carbapenemase-negative K. pneumoniae, relatively high MICHIs are seen with OXA-48 carbapenemase producers and the highest MICHI values were detected with KPC and NDM producers. In general, meropenem activity against K. pneumoniae at high inocula depends on the ability of bacteria to produce specific types of carbapenemases.
Along with using absolute MICs at high and standard inocula for inter-MIC correlations, we analyzed the relationship between the initial MICs at SI and the ratio of MICHI to MIC (MIC shift, IE measure). This analysis was aimed at exploring whether IE occurrence depends on the isolate’s initial MIC and if it can be predicted based on MIC data alone (Figure 2). As seen in Figure 2, sigmoid “MICHI/MIC ratio—MIC” relationships with high correlation coefficients (r2 = 0.86–0.92) were obtained for all isolate groups: the higher the isolate’s MIC at standard inocula, the lesser the inoculum-related MIC decrease and IE probability. As mentioned above, carbapenemase-non-producing K. pneumoniae were less prone to the IE than carbapenemase producers and were characterized by less inoculum-related MIC decreases. OXA-48 producers were not prone to the IE if the isolate MIC was higher than the meropenem MIC breakpoint; even with high meropenem MICs (up to 32 and 64 mg/L, respectively), KPC and NDM producers exhibited the IE at high inocula.

2.2. MPC Determination of Meropenem against K. pneumoniae

The MPC data for K. pneumoniae strains are presented in Table 1. MPCs varied over a wide range depending on the isolate and its ability to produce carbapenemase. The smallest MPC values were determined for carbapenemase-non-producing K. pneumoniae; with most strains the MPC ranged from 1 to 8 mg/L. These MPC values were very close to MICHI values. MPCs of carbapenemase-producing K. pneumoniae were significantly higher than carbapenemase-negative strains. However, considerable MPC differences among the strain groups were observed. For example, K. pneumoniae strains with equal meropenem MICs (8 mg/L) but producing different carbapenemase types (3111, 1904 and 2131), had MPCs that differed by an order of magnitude: 128 mg/L for OXA-48 producer versus 2048 for both KPC and NDM producers, respectively. In total, meropenem MPC range for OXA-48 producers was from 32 to 256 mg/L, while for KPC and NDM producers, it was from 1024 to 8192 mg/L.
To examine correlations between the MICs and the MPCs, the respective data for all K. pneumoniae strains were plotted on one graph (Figure 3). As seen in the figure, no correlation could be found between the MICs and the MPCs regardless of the isolate and its ability to produce any carbapenemases. However, there is some MPC data stratification among the strains: the lowest values were in carbapenemase-negative K. pneumoniae, were a little higher with OXA-48 producers and were higher still in KPC and NDM producers.
Assuming that both MICHI and MPC are the resistance measures that display “hidden” bacterial resistance potential, we plotted these strain characteristics on the same graph in an attempt to find any correlation between these resistance measures (Figure 4).
As seen in the figure, a distinct sigmoid relationship was observed between the MICHIs and the MPCs based on the merged data for all K. pneumoniae strains with r2 = 0.93. Interestingly, the data points that belong to different K. pneumoniae groups (carbapenemase-negative, OXA-48, KPC and NDM producers) follow each other with respect to MICHI increases. The lowest MICHI and MPC values were seen with carbapenemase-non-producing K. pneumoniae; then, OXA-48 producers follow and the highest MICHI and MPC values were seen with KPC- and NDM-producing strains.

3. Discussion

In the current study, we have provided a comprehensive analysis of “resistance profiles” of K. pneumoniae strains that differ by meropenem susceptibility, ability to produce carbapenemases and specific carbapenemase types.
We found that meropenem susceptibility of carbapenemase-producing K. pneumoniae was significantly influenced by the bacterial inoculum density, and IE was most often detected with these isolates. In contrast, non-carbapenemase-producing K. pneumoniae isolates were not usually prone to the IE and inoculum-induced meropenem MIC increase was minimal except for in the two most susceptible strains. These results are concordant with many other in vitro studies where the beta-lactam IE was confirmed most often with beta-lactamase-producing Gram-negative bacteria [17]. In the current study, among carbapenemase-producing isolates, NDM producers were characterized by significantly higher inoculum-related MIC increases (up to the 256-fold); KPC- and OXA-48-producing strains exhibited relatively lower MIC shifts (Table 1).
Assuming the possible threat of IE when treating patients with infections caused by Gram-negatives, it would be valuable if this phenomenon could be predicted with given bacterial isolates and antibiotics in order to optimize therapy. The current study did not find a relationship between MIC and MICH for carbapenemase-producing K. pneumoniae (Figure 1). With the control group of non-carbapenemase-producing strains, a poor “MICHI-MIC” correlation was observed (r2 = 0.65). Hence, MIC itself cannot predict specific MICHI values for a given K. pneumoniae strain. However, it was shown that the MIC shift at high inocula, i.e., MICHI/MIC ratio, does correlate with the initial MIC (Figure 2); therefore, assuming the initial meropenem MIC value, we can predict possible decreases in meropenem susceptibility at high inocula. Interestingly, the higher the MIC of isolate at SI, the weaker the MIC decrease at high inocula was observed; this was seen with both carbapenemase-producing and non-carbapenemase-producing K. pneumoniae. From our previous results with imipenem and doripenem alone or in combination with the carbapenemase inhibitor relebactam, the IE was more likely when K. pneumoniae MIC was lower [33]. With highly carbapenem resistant K. pneumoniae isolates, the IE was not observed. This can be explained by potentiation of carbapenemase enzymes with inoculum increases in strains with lower initial MICs than in highly resistant strains which already possess high carbapenemase activity.
Unfortunately, IE was detected in all meropenem-susceptible carbapenemase producers. This causes concern about decreased meropenem clinical results in treating high-density infections caused by these organisms given that their meropenem MICHIs exceed peak therapeutic plasma meropenem concentration with a standard dosing regimen (approximately 30 mg/L after a standard dose of 1 g intravenously every 8 h [34,35]) or exceed the meropenem concentrations for most of the dosing interval with a high-dose meropenem regimen (approximately 40 mg/L after a dose of 2 g intravenously every 8 h [36]).
The MPC is a well-known measure of bacterial ability to produce antibiotic-resistant cells. Based on the MSW hypothesis, the MPC value can be used to assess whether certain microbes pose a high risk of decreased antibacterial effectiveness due to the development of resistance. In the MPC-analysis of our K. pneumoniae strains, we detected mostly low MPC values for carbapenemase-non-producing strains (1–8 mg/L), while carbapenemase producers in general exhibited high MPCs (32 mg/L at minimum); therefore, the “hidden” resistance potential of such strains is very high. Among carbapenemase producers, the MPCs of OXA-48-producing isolates were prominently lower than those of KPC- and NDM-producing isolates (about an order of magnitude). Possibly, it can be explained by the ability of different bacterial cells, depending on carbapenemase type, to enhance carbapenemase gene expression under the influence of meropenem. At high inoculum these differences multiply and lead to significant differences as well as in MPC and MICHI values. Previously, the increased expression of levels of beta-lactamase genes in K. pneumoniae under the influence of meropenem was reported [37]. Similarly, as at MICHI, assuming therapeutic plasma meropenem concentrations (after administration of a 1 g standard or 2 g high dose [34,35,36]), the success of meropenem therapy is highly probable against carbapenemase-negative meropenem susceptible K. pneumoniae. In contrast, if the key pathogen is a carbapenemase producer, there is a high probability of meropenem resistance due to the high MPC that exceeds peak meropenem concentration, and the antibiotic pharmacokinetic profile would be inside the MSW for most of the dosing interval.
As mentioned above, MPCs did not correlate with initial antibiotic MICs (the lower border of MSW) and, therefore, could not be predicted by the MIC (Figure 3). Similar conclusions about weak or absent correlations between the MIC and MPC have been reported with several classes of antibiotics [38,39]. Obviously, it would be very helpful at the initial stage of antimicrobial therapy, when the bacterial isolate is identified and screened for antibiotic susceptibility, if we could predict possible resistance-related treatment outcomes. In this light, we questioned whether, instead of standard MICs, the MIC determined at high bacterial inocula could be used for this purpose and if MICHI would correlate with the MPC, as both measures represent the “hidden” resistance potential. This might be important and practical because assessing MICHI (to characterize the “hidden” bacterial resistance potential) is much easier than MPC testing, which is not widely available in routine laboratory testing.
The results showed that MPC correlated well with MICHI (in contrast to MIC): the higher the MICHI the higher the MPC (Figure 4). The combined data for all K. pneumoniae strains were fitted by a single sigmoid function with a very high correlation coefficient (r2 = 0.93). This indicates that the MICHI can be used to predict the isolate’s MPC (independent of the production of carbapenemases). Furthermore, along with MPC, MICHI-based pharmacokinetic/pharmacodynamic (PK/PD) indices, such as the percent of time when antibiotic concentration exceeds the MIC within the dosing interval, %T > MICHI [40] and the ratio of the area under the concentration versus time curve (AUC) to the MICHI, AUC/MICHI, can be used to construct “resistance-concentration” relationships. Using such relationships, it is possible to determine antibiotic regimens that could suppress resistance development. Therefore, we propose a series of in vitro studies using dynamic models to delineate relationships between MICHI-based PK/PD indices and the development of meropenem resistance in carbapenemase-producing and non-producing K. pneumoniae.
In summary, the high MICHI and MPC values for carbapenemase-producing K. pneumoniae predict low meropenem efficacy against high-burden infections caused by these pathogens.
The study has several limitations: it did not include bacterial strains other than K. pneumoniae or other beta-lactam antibiotics that could generalize the current conclusions.

4. Materials and Methods

4.1. Antimicrobial Agent and Bacterial Strains

Meropenem powder was purchased from Sigma-Aldrich (St. Louis, MO, USA). Thirty-nine in total K. pneumoniae, including clinical isolates and ATCC collection strains (700603 and KPC reference strains: BAA 1705 and BAA 1898, BAA 1899, BAA 1900, BAA 1902, BAA 1904, and BAA 1905), with different susceptibility to meropenem in range from susceptible to resistant (according to EUCAST recommendations to use meropenem susceptibility MIC breakpoint of ≤8 mg/L [34]) were used in the study. Ten of them were carbapenemase non-producing, ten by each of blaOXA-48 and blaNDM positive by PCR and nine of blaKPC positive by PCR. Before each testing, carbapenemase production was double-checked for each bacterial strain by a modified carbapenem-inactivation method [41]. Thirty-one clinical isolates were collected from ICU patients admitted to the Moscow and Saint Petersburg hospitals. The sites of isolation were blood, sputum, urine and tracheal aspirate.

4.2. Susceptibility Testing

Susceptibility testing of K. pneumoniae to meropenem at standard inocula (SI) of approximately 5 × 105 CFU/mL was performed using broth microdilution technique with a series of two-fold dilutions according to the CLSI recommendations [42]. A similar technique was used for susceptibility testing at high inocula of 5 × 107 CFU/mL (HI). For all MIC testing experiments, the Mueller–Hinton broth (MHB) (Becton Dickinson, San Jose, CA, USA) was used. When the meropenem MICs were determined at HI, bacterial growth was quantified by optical density at 600 nm (OD), ODs before and after 18 h incubation at 37 °C were estimated. The MIC was the dilution at which the 18 h OD was equal to or less than that at time 0. An inoculum effect was defined as an eightfold or greater increase in MIC when tested with the HI and compared to that for SI [13]. MIC testing was repeated at least three times each with double replicates, and then the modal MICs were estimated.
The MIC breakpoint for meropenem susceptibility was used according to EUCAST recommendations [34]. The interpretive criteria for susceptibility were as follows: susceptible, ≤2 mg/L; resistant, >8 mg/L.

4.3. Mutant Prevention Concentration (MPC) Determinations

The meropenem MPC for each K. pneumoniae isolate was determined as described elsewhere [43,44]. Briefly, the tested microorganism was cultured in MHB and incubated for 24 h. Then, the bacterial suspension was centrifuged (4000× g for 20 min) and, after the removing of the supernatant, the pellet was re-suspended in MHB to yield a concentration of ~1010 CFU/mL. A series of agar plates (Mueller–Hinton agar) containing meropenem concentrations ranging from 0.03 to 8192 mg/L were then inoculated with a ~1010 CFU/mL suspension of K. pneumoniae, incubated for 24–48 h at 37 °C and screened visually for growth. The plates with a weak or doubtful bacterial growth were additionally stroked to the agar plates with similar meropenem concentration and incubated for 24–48 h. Then, the presence or absence of microbial growth was estimated. The MPC was taken as the lowest meropenem concentration that completely inhibited growth. The lower limit of detection was 10 CFU/mL (equivalent to at least one colony per plate). The MPC determination was repeated for each K. pneumoniae strain at least in triplicate.

4.4. Statistical Analysis

The reported MIC, MICHI and MPC data were obtained by calculation of the respective modal values.
The relationship between the MIC and MICHI data (both expressed in decimal logarithms) was fitted by the sigmoid function:
Y = Y0 + a/{1 + exp[−(x − x0)/b]}
where Y is log MICHI; Y0 is minimal value of Y; x is log MIC; a is maximal value of Y; x0 is x corresponding to a/2; b is a parameter reflecting sigmoidicity.
The relationships between the MIC and MICHI/MIC ratio and between the MICHI and MPC (all expressed in decimal logarithms) were fitted by the sigmoid function:
Y = a/{1 + exp[−(x − x0)/b]}
where Y is log MICHI/MIC ratio or log MPC; x is log MIC or log MICHI; a is maximal value of Y; x0 is x corresponding to a/2; b is a parameter reflecting sigmoidicity.
All calculations were performed using SigmaPlot 12 software (Systat Software Inc., headquartered in San Jose, CA, USA).

5. Conclusions

The current study shows low IE probability with carbapenemase-non-producing K. pneumoniae and high IE probability with carbapenemase-producing strains. The IE probability can be assumed from the MIC of a given K. pneumoniae strain using established “MICHI/MIC ratio—MIC” relationships. We determined the general trend—the higher the meropenem MIC, the less meropenem activity will diminish at high bacterial burdens. Among tested carbapenemase-producing strains, OXA-48 producers exhibited the lowest inoculum-related MIC shifts, KPC- and NDM-producing bacteria exhibited quite high meropenem MICs at high inocula and MIC did not correlate with the MPC values. In contrast, a significant correlation was observed between the MICHIs and the MPC, indicating that these bacteria-antibiotic characteristics are inter-related and describes the “hidden” bacterial resistance potential. To determine the possible resistance-related risk of failure outcome due to a given K. pneumoniae strain, we propose determining the MICHI. This can more or less predict the MPC value of the particular strain. Along with MPC, MICHI (as part of PK/PD indices) can be used to construct “resistance-concentration” relationships.

Author Contributions

Conceptualization, M.V.G., E.N.S. and S.H.Z.; methodology, M.V.G., E.N.S. and S.H.Z.; software, K.N.A.; validation, K.N.A.; formal analysis, K.N.A., O.S.S. and A.A.A.; investigation, E.N.S., M.V.G., K.N.A., V.A.A., O.S.S. and A.A.A.; resources, V.A.A.; data curation, E.N.S., K.N.A., O.S.S. and A.A.A.; writing—original draft preparation, M.V.G., E.N.S. and S.H.Z.; writing—review and editing, M.V.G., E.N.S., V.A.A. and S.H.Z.; visualization, M.V.G. and E.N.S.; supervision, M.V.G., E.N.S. and V.A.A.; project administration, M.V.G. and E.N.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by The Russian Science Foundation (grant number 21-74-10090).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Magréault, S.; Jauréguy, F.; Carbonnelle, E.; Zahar, J.R. When and how to use MIC in clinical practice? Antibiotics 2022, 11, 1748. [Google Scholar] [CrossRef] [PubMed]
  2. Drlica, K.; Zhao, X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 2007, 44, 681–688. [Google Scholar] [CrossRef] [PubMed]
  3. Cantón, R.; Morosini, M.-I. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol. Rev. 2011, 35, 977–991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Croisier, D.; Etienne, M.; Bergoin, E.; Charles, P.E.; Lequeu, C.; Piroth, L.; Portier, H.; Chavanet, P. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 2004, 48, 1699–1707. [Google Scholar] [CrossRef] [Green Version]
  5. Firsov, A.A.; Vostrov, S.N.; Lubenko, I.Y.; Drlica, K.; Portnoy, Y.A.; Zinner, S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus Aureus. Antimicrob. Agents Chemother. 2003, 47, 1604–1613. [Google Scholar] [CrossRef] [Green Version]
  6. Fujimura, S.; Nakano, Y.; Watanabe, A. A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin. J. Infect. Chemother. 2014, 20, 752–756. [Google Scholar] [CrossRef]
  7. Firsov, A.A.; Smirnova, M.V.; Lubenko, I.Y.; Vostrov, S.N.; Portnoy, Y.A.; Zinner, S.H. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother. 2006, 58, 1185–1192. [Google Scholar] [CrossRef]
  8. Firsov, A.A.; Alieva, K.N.; Strukova, E.N.; Golikova, M.V.; Portnoy, Y.A.; Dovzhenko, S.A.; Kobrin, M.B.; Romanov, A.V.; Edelstein, M.V.; Zinner, S.H. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J. Antimicrob. Chemother. 2017, 72, 3100–3107. [Google Scholar] [CrossRef] [Green Version]
  9. Allen, G.P.; Deshpande, L.M. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 2010, 35, 45–49. [Google Scholar] [CrossRef]
  10. Li, Y.; Feng, B.; Gu, X.; Yang, D.; Zeng, Z.; Zhang, B.; Ding, H. Correlation of PK/PD Indices with resistance selection for cefquinome against Staphylococcus aureus in an in vitro model. Front. Microbiol. 2016, 7, 466. [Google Scholar] [CrossRef] [Green Version]
  11. Zinner, S.H.; Gilbert, D.; Greer, K.; Portnoy, Y.A.; Firsov, A.A. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chemother. 2013, 68, 881–887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Vassilara, F.; Galani, I.; Souli, M.; Papanikolaou, K.; Giamarellou, H.; Papadopoulos, A. Mechanisms responsible for imipenem resistance among Pseudomonas aeruginosa clinical isolates exposed to imipenem concentrations within the mutant selection window. Diagn. Microbiol. Infect. Dis. 2017, 88, 276–281. [Google Scholar] [CrossRef] [PubMed]
  13. Brook, I. Inoculum effect. Rev. Infect. Dis. 1989, 11, 361–368. [Google Scholar] [CrossRef]
  14. Kebriaei, R.; Rice, S.A.; Singh, K.V.; Stamper, K.C.; Dinh, A.Q.; Rios, R.; Diaz, L.; Murray, B.E.; Munita, J.M.; Tran, T.T.; et al. Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with β-Lactams against daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Antimicrob. Agents Chemother. 2018, 62, e00315-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Lee, D.G.; Murakami, Y.; Andes, D.R.; Craig, W.A. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob. Agents Chemother. 2013, 57, 1434–1441. [Google Scholar] [CrossRef] [Green Version]
  16. Kim, T.; Lee, S.C.; Bae, M.; Sung, H.; Kim, M.-N.; Jung, J.; Kim, M.J.; Kim, S.-H.; Lee, S.-O.; Choi, S.-H.; et al. In vitro activities and inoculum effects of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant Enterobacterales isolates from South Korea. Antibiotics 2020, 9, 912. [Google Scholar] [CrossRef] [PubMed]
  17. Lenhard, J.R.; Bulman, Z.P. Inoculum effect of β-lactam antibiotics. J. Antimicrob. Chemother. 2019, 74, 2825–2843. [Google Scholar] [CrossRef]
  18. Lenhard, J.R.; Gall, J.S.; Bulitta, J.B.; Thamlikitkul, V.; Landersdorfer, C.B.; Forrest, A.; Nation, R.L.; Li, J.; Tsuji, B.T. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter Baumannii. Int. J. Antimicrob. Agents 2016, 48, 719–724. [Google Scholar] [CrossRef] [Green Version]
  19. Harada, Y.; Morinaga, Y.; Kaku, N.; Nakamura, S.; Uno, N.; Hasegawa, H.; Izumikawa, K.; Kohno, S.; Yanagihara, K. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin. Microbiol. Infect. 2014, 20, O831-9. [Google Scholar] [CrossRef] [Green Version]
  20. Miller, W.R.; Singh, K.V.; Arias, C.A.; Murray, B.E. Adjunctive clavulanic acid abolishes the cefazolin inoculum effect in an experimental rat model of methicillin-sensitive Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 2018, 62, e01158-18. [Google Scholar] [CrossRef] [Green Version]
  21. Nannini, E.C.; Singh, K.V.; Arias, C.A.; Murray, B.E. In Vivo effects of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin. Antimicrob. Agents Chemother. 2013, 57, 4276–4281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Singh, K.V.; Tran, T.T.; Nannini, E.C.; Tam, V.H.; Arias, C.A.; Murray, B.E. Efficacy of ceftaroline against methicillin-susceptible Staphylococcus aureus exhibiting the cefazolin high-inoculum effect in a rat model of endocarditis. Antimicrob. Agents Chemother. 2017, 61, e00324-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Docobo-Pérez, F.; López-Cerero, L.; López-Rojas, R.; Egea, P.; Domínguez-Herrera, J.; Rodríguez-Baño, J.; Pascual, A.; Pachón, J. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob. Agents Chemother. 2013, 57, 2109–2113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Soriano, F.; Santamaría, M.; Ponte, C.; Castilla, C.; Fernández-Roblas, R. In vivo significance of the inoculum effect of antibiotics on Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7, 410–412. [Google Scholar] [CrossRef] [PubMed]
  25. Smelter, D.; McCrone, S.; Rose, W. Cefazolin inoculum effect predicts reduced susceptibility to other antibiotics and patient outcomes in MSSA endovascular infections. Open Forum Infect. Dis. 2020, 7 (Suppl. 1), S617. [Google Scholar] [CrossRef]
  26. Miller, W.R.; Seas, C.; Carvajal, L.P.; Diaz, L.; Echeverri, A.M.; Ferro, C.; Rios, R.; Porras, P.; Luna, C.; Gotuzzo, E.; et al. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia. Open Forum Infect. Dis. 2018, 5, ofy123. [Google Scholar] [CrossRef] [Green Version]
  27. Poirel, L.; Bonnin, R.A.; Nordmann, P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob. Agents Chemother. 2012, 56, 559–562. [Google Scholar] [CrossRef] [Green Version]
  28. Rodrigues, Y.C.; Lobato, A.R.F.; Quaresma, A.J.P.G.; Guerra, L.M.G.D.; Brasiliense, D.M. The spread of NDM-1 and NDM-7-producing Klebsiella pneumoniae is driven by multiclonal expansion of high-risk clones in healthcare institutions in the state of Pará, Brazilian Amazon Region. Antibiotics 2021, 10, 1527. [Google Scholar] [CrossRef]
  29. Mulvey, M.R.; Grant, J.M.; Plewes, K.; Roscoe, D.; Boyd, D.A. New Delhi metallo-β-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg. Infect. Dis. 2011, 17, 103–106. [Google Scholar] [CrossRef]
  30. Cuzon, G.; Naas, T.; Truong, H.; Villegas, M.V.; Wisell, K.T.; Carmeli, Y.; Gales, A.C.; Venezia, S.N.; Quinn, J.P.; Nordmann, P. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg. Infect. Dis. 2010, 16, 1349–1356. [Google Scholar] [CrossRef]
  31. Reale, M.; Strazzulla, A.; Quirino, A.; Rizzo, C.; Marano, V.; Postorino, M.C.; Mazzitelli, M.; Greco, G.; Pisani, V.; Costa, C.; et al. Patterns of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: Implications for empirical therapy and infection control. Infez. Med. 2017, 25, 98–107. [Google Scholar] [PubMed]
  32. Scaglione, V.; Reale, M.; Davoli, C.; Mazzitelli, M.; Serapide, F.; Lionello, R.; La Gamba, V.; Fusco, P.; Bruni, A.; Procopio, D.; et al. Prevalence of antibiotic resistance over time in a third-level University Hospital. Microb. Drug Resist. 2022, 28, 425–435. [Google Scholar] [CrossRef] [PubMed]
  33. Golikova, M.V.; Alieva, K.N.; Filimonova, A.V.; Ageevets, V.A.; Sulian, O.S.; Avdeeva, A.A.; Sidorenko, S.V.; Zinner, S.H. Klebsiella pneumoniae susceptibility to carbapenem/relebactam combinations: Influence of inoculum density and carbapenem-to-inhibitor concentration ratio. Biomedicines 2022, 10, 1454. [Google Scholar] [CrossRef] [PubMed]
  34. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 13.0, 2023. Available online: http://www.eucast.org (accessed on 12 April 2023).
  35. Mouton, J.W.; van den Anker, J.N. Meropenem clinical pharmacokinetics. Clin. Pharmacokinet. 1995, 28, 275–286. [Google Scholar] [CrossRef] [PubMed]
  36. Dandekar, P.K.; Maglio, D.; Sutherland, C.A.; Nightingale, C.H.; Nicolau, D.P. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003, 23, 988–991. [Google Scholar] [CrossRef]
  37. Adler, A.; Ben-Dalak, M.; Chmelnitsky, I.; Carmeli, Y. Effect of resistance mechanisms on the inoculum effect of carbapenem in Klebsiella pneumoniae isolates with borderline carbapenem resistance. Antimicrob. Agents Chemother. 2015, 59, 5014–5017. [Google Scholar] [CrossRef] [Green Version]
  38. Lozano-Huntelman, N.A.; Singh, N.; Valencia, A.; Mira, P.; Sakayan, M.; Boucher, I.; Tang, S.; Brennan, K.; Gianvecchio, C.; Fitz-Gibbon, S.; et al. Evolution of antibiotic cross-resistance and collateral sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the mutant selection window. Evol. Appl. 2020, 13, 808–823. [Google Scholar] [CrossRef] [Green Version]
  39. Gugel, J.; Dos Santos Pereira, A.; Pignatari, A.C.; Gales, A.C. beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50, 2276–2277. [Google Scholar] [CrossRef] [Green Version]
  40. Mouton, J.M.; Punt, N. Use of the t > MIC to choose between different dosing regimens of β-lactam antibiotics. J. Antimicrob. Chemother. 2001, 47, 500–501. [Google Scholar] [CrossRef] [Green Version]
  41. Van der Zwaluw, K.; de Haan, A.; Pluister, G.N.; Bootsma, H.J.; de Neeling, A.J.; Schouls, L.M. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS ONE 2015, 10, e0123690. [Google Scholar] [CrossRef] [Green Version]
  42. Clinical Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.; M07; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2019. [Google Scholar]
  43. Blondeau, J.M. New concepts in antimicrobial susceptibility testing: The mutant prevention concentration and mutant selection window approach. Vet. Dermatol. 2009, 20, 383–396. [Google Scholar] [CrossRef] [PubMed]
  44. Firsov, A.A.; Portnoy, Y.A.; Strukova, E.N.; Shlykova, D.S.; Zinner, S.H. Predicting bacterial resistance using the time inside the mutant selection window: Possibilities and limitations. Int. J. Antimicrob. Agents 2014, 44, 301–305. [Google Scholar] [CrossRef] [PubMed]
Antibiotics 12 00872 g001 550
Figure 1. MICHI versus MIC data with meropenem and K. pneumoniae. Vertical dashed line indicates meropenem susceptibility MIC breakpoint of 8 mg/L. Data for carbapenemase-non-producing strains were fitted by Equation (1): Y0 = 0.008, x0 = 20.4526, a = 57332, b = 1.7718. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Figure 1. MICHI versus MIC data with meropenem and K. pneumoniae. Vertical dashed line indicates meropenem susceptibility MIC breakpoint of 8 mg/L. Data for carbapenemase-non-producing strains were fitted by Equation (1): Y0 = 0.008, x0 = 20.4526, a = 57332, b = 1.7718. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Antibiotics 12 00872 g001
Antibiotics 12 00872 g002 550
Figure 2. “MICHI/MIC ratio—MIC” relationships with meropenem and K. pneumoniae fitted by Equation (2): x0 = −0.2134, a = 1.7495, b = −0.3573 (CARB-); x0 = 0.7329, a = 1.7362, b = −0.4657 (OXA-48 producers); x0 = 1.6671, a = 1.5557, b = −0.5255 (KPC producers); x0 = 1.2069, a = 2.86, b = −0.8116 (NDM producers). Vertical dashed line indicates the meropenem susceptibility MIC breakpoint of 8 mg/L. Horizontal dashed line indicates the threshold MICHI/MIC ratio equal to 8 and associated with the IE. Red and green areas indicate the MICHI/MIC levels are associated and not associated with IE, respectively. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Figure 2. “MICHI/MIC ratio—MIC” relationships with meropenem and K. pneumoniae fitted by Equation (2): x0 = −0.2134, a = 1.7495, b = −0.3573 (CARB-); x0 = 0.7329, a = 1.7362, b = −0.4657 (OXA-48 producers); x0 = 1.6671, a = 1.5557, b = −0.5255 (KPC producers); x0 = 1.2069, a = 2.86, b = −0.8116 (NDM producers). Vertical dashed line indicates the meropenem susceptibility MIC breakpoint of 8 mg/L. Horizontal dashed line indicates the threshold MICHI/MIC ratio equal to 8 and associated with the IE. Red and green areas indicate the MICHI/MIC levels are associated and not associated with IE, respectively. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Antibiotics 12 00872 g002
Antibiotics 12 00872 g003 550
Figure 3. MPC versus MIC data with meropenem and K. pneumoniae. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Figure 3. MPC versus MIC data with meropenem and K. pneumoniae. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48-producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Antibiotics 12 00872 g003
Antibiotics 12 00872 g004 550
Figure 4. The “MPC—MICHI” relationship with meropenem and K. pneumoniae fitted by Equation (2): x0 = 1.4167, a = 3.8256, b = 0.5702. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Figure 4. The “MPC—MICHI” relationship with meropenem and K. pneumoniae fitted by Equation (2): x0 = 1.4167, a = 3.8256, b = 0.5702. “CARB−“is carbapenemase-negative group of strains; “OXA-48” is OXA-48producing group of strains; “KPC” is KPC-producing group of strains; “NDM” is NDM-producing group of strains.
Antibiotics 12 00872 g004
Table
Table 1. MICs (mg/L) at standard (MIC) and high inocula (MICHI) data, MICHI/MIC ratios and MPCs (mg/L) of meropenem against carbapenemase-producing and carbapenemase-non-producing K. pneumoniae strains.
Table 1. MICs (mg/L) at standard (MIC) and high inocula (MICHI) data, MICHI/MIC ratios and MPCs (mg/L) of meropenem against carbapenemase-producing and carbapenemase-non-producing K. pneumoniae strains.
CarbapenemaseK. pneumoniaeMICMICHIMICHI/MICIE 1MPC
Carbapenemase-negative
(n = 10)		700,6030.03264+4
1880.06232+1
782144 − 4
2286221−2
2684242−4
3093284−64
3101284−4
1676441−8
844881−8
289516161−128
OXA-48 carbapenemase
producers (n = 10)		12780.53264+128
112811616+32
21511616+64
145626432+256
11704328+128
31118648+128
20216322−128
3816322−256
48516644−256
7532642−64
KPC carbapenemase
producers (n = 9)		BAA 1904812816+2048
BAA 17051625616+1024
BAA 1900322568+1024
14322568+4096
BAA 1898642564−2048
BAA 1899642564−2048
BAA 19021282562−2048
BAA 19051285124−2048
161285124−2048
NDM carbapenemase
producers (n = 10)		13262256128+1024
22282512256+4096
2342425664+4096
35425664+4096
1167825632+1024
2131851264+2048
3204851264+2048
19613251216+4096
31663251216+2048
2863645128+8192
1 IE—inoculum effect, ≥8-fold MIC increase at high inocula of 5 × 107 CFU/mL (HI); “+” indicates the IE was observed; “−“ indicates the IE was not observed.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Golikova, M.V.; Strukova, E.N.; Alieva, K.N.; Ageevets, V.A.; Avdeeva, A.A.; Sulian, O.S.; Zinner, S.H. Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae. Antibiotics 2023, 12, 872. https://doi.org/10.3390/antibiotics12050872

AMA Style

Golikova MV, Strukova EN, Alieva KN, Ageevets VA, Avdeeva AA, Sulian OS, Zinner SH. Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae. Antibiotics. 2023; 12(5):872. https://doi.org/10.3390/antibiotics12050872

Chicago/Turabian Style

Golikova, Maria V., Elena N. Strukova, Kamilla N. Alieva, Vladimir A. Ageevets, Alisa A. Avdeeva, Ofeliia S. Sulian, and Stephen H. Zinner. 2023. "Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae" Antibiotics 12, no. 5: 872. https://doi.org/10.3390/antibiotics12050872

APA Style

Golikova, M. V., Strukova, E. N., Alieva, K. N., Ageevets, V. A., Avdeeva, A. A., Sulian, O. S., & Zinner, S. H. (2023). Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae. Antibiotics, 12(5), 872. https://doi.org/10.3390/antibiotics12050872

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop